Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology, Inc. announced that President & Chief Operating Officer Ambaw Bellete will separate from the company effective June 30, 2026, following an agreement reached on May 20, 2026. He is expected to receive severance benefits consistent with Section 4(b) of his 2025 employment agreement.
The company has begun a search for a Chief Commercial Officer and the board has appointed Arthur Kuan as President in addition to his existing roles. His background is described in CG Oncology’s definitive proxy statement filed on April 24, 2026.
CG Oncology Inc disclosure: T. Rowe Price Investment Management, Inc. reports 6,720,389 shares of Common Stock, representing 8.0% of the class as of 03/31/2026. The filing lists 6,459,822 shares of sole voting power and affirms that the filer denies beneficial ownership in the filing's declaration. The signature block is dated 05/15/2026.
CG Oncology, Inc. Schedule 13G discloses that RTW Investments, LP and Roderick Wong report shared beneficial ownership of 6,984,808 shares of Common Stock, representing 8.3% of the class based on 84,435,200 shares outstanding as of February 25, 2026.
The filing states the RTW Funds have the right to receive dividends or sale proceeds on these shares. The Reporting Persons report no sole voting or dispositive power; all voting and dispositive power is shared.
CG Oncology, Inc. reported a larger net loss as it invests heavily in late-stage bladder cancer programs while strengthening its balance sheet. For the three months ended March 31, 2026, total revenue was $1.1 million, including $1.1 million of commercial and development revenue from Biovire and a small amount of license revenue. Operating expenses rose to $67.5 million, driven by $43.7 million in research and development and $20.8 million in general and administrative costs, leading to a net loss of $60.2 million versus $34.5 million a year earlier.
The company ended March 31, 2026 with $1,076.2 million in cash, cash equivalents and marketable securities, supported by $391.4 million of net proceeds from an at-the-market offering during the quarter. As of that date, accumulated deficit was $439.2 million and 88,007,761 common shares were outstanding. Management believes existing funds can support operations for at least twelve months while it advances its Biologics License Application for cretostimogene grenadenorepvec in non-muscle invasive bladder cancer.
CG Oncology, Inc. reported first quarter 2026 results and updated progress on its bladder cancer programs. Total revenue was $1.1 million, up from $52 thousand a year earlier, while the company recorded a net loss of $60.2 million, or $(0.71) per share.
Research and development expenses rose to $43.7 million and general and administrative expenses to $20.8 million, reflecting higher clinical and personnel costs. Cash, cash equivalents and marketable securities were $1.1 billion as of March 31, 2026, including $391.4 million of net proceeds from selling 6,941,407 shares through an at-the-market facility, which the company expects will fund operations through 2029.
CG Oncology highlighted completion of non-clinical and clinical modules for its first BLA for high‑risk BCG‑unresponsive non‑muscle invasive bladder cancer, with full submission targeted for the fourth quarter of 2026. The company anticipates topline Phase 3 PIVOT‑006 data and first Phase 2 CORE‑008 Cohort CX results in the first half of 2026.
CG Oncology, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026 at 10:00 a.m. Pacific Time. Holders of common stock at the close of business on April 7, 2026, when 88,009,980 shares were outstanding, may vote.
Stockholders will elect two Class II directors, Christina Rossi and Victor Tong Jr., to terms ending at the 2029 annual meeting, ratify Ernst & Young LLP as independent auditor for 2026, approve on an advisory basis executive compensation, and choose how often future advisory votes on pay should occur.
The company highlights its classified board, independent committee structure, risk oversight framework, and use of performance-based and equity incentives. The meeting will be conducted exclusively online via webcast, with voting and questions available through the designated proxy website.
CG Oncology director James Mulay reported an exercise-and-sale transaction in the company’s common stock. On April 17, 2026, he exercised options to acquire 15,600 shares of common stock at $36.63 per share, then sold the same 15,600 shares in an open-market transaction at a weighted average price of $73.01 per share.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 6, 2025, indicating they were scheduled in advance rather than timed discretionarily. After these transactions, Mulay reported holding no shares of common stock or related director stock options directly.
James Mule filed a Form 144 proposing the sale of 17,564 shares of Common stock on 04/17/2026. The sale is listed as an Exercise of Stock Options with cash proceeds. The filing also shows prior 10b5-1 sales of 1,964 shares on 03/16/2026 for $124,714.
CG Oncology, Inc. reported that President and COO Bellete Ambaw received a grant of employee stock options. The award covers 107,508 options to buy common stock at an exercise price of $67.68 per share, expiring on April 14, 2036.
According to the footnote, 1/48th of the options vest monthly after the April 15, 2026 vesting commencement date, contingent on Ambaw’s continuous service. Following this grant, Ambaw directly holds 107,508 derivative securities linked to CG Oncology common stock.